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oronary angiography presently remains the main 
method for the diagnosis and instruction of epicardial 
coronary disease. However, precise characterization of 
the significance for any given stenosis is limited by the 
inability to identify intermediate coronary lesions 
responsible for ischemia.1-3 In clinical practice, in 
addition to the assessment of the anatomical details of 
vessel narrowing, a more precise assessment of the 
impediment to coronary blood flow has become 
extremely important. At present, several physiological 
parameters have been introduced to improve 
discrimination in functional coronary lesion severity 
during cardiac catheterization. Of these parameters, 
myocardial fractional flow reserve (FFR) has been the 
most frequently used and is being increasingly applied to 
assess the functional significance of intermediate lesions. 
FFR can provide important information, both for decision 
making in diagnostic angiography and for monitoring and 
evaluating coronary interventions.3,4  
 
FFR is the ratio of maximum hyperemic blood flow in the 
presence of a coronary artery stenosis to the normal 
hyperemic blood flow in the same vessel in case of the 
absence of stenosis, FFR=Pd–Pv/Pa–Pv (Pa is the mean 
aortic pressure measured with the guiding catheter, Pd is 
the pressure measured from the pressure-sensing guide 
wire distal from the stenosis and Pv is the central venous 
pressure, all measured at maximum coronary hyperemia). 
Although the complete formula for measuring FFR uses 
venous pressure, generally it can be neglected unless 
there are clinical indications that venous pressure is 
markedly elevated, or specific studies of collateral blood 
flow are anticipated. Therefore, FFR can be expressed as 
the ratio of the maximum hyperemic mean distal coronary 
artery pressure and the aortic pressure, i.e. FFR=Pd/Pa.1-7 
In a normal artery without stenosis, FFR has an 
unequivocal value of 1.0. This index is relatively 
independent of changes in systemic blood pressure, heart 
rate and myocardial contractility.3,8 The established 
threshold value of FFR is <0.75, which implies that the 
stenosis is considered significant and shows a good 
agreement with exercise electrocardiogram, dobutamine 
stress echocardiography and stress perfusion 
scintigraphy.3,4,7,9,10  
                      
METHODS 
 
After the insertion of a sheath in the femoral artery, a 
6-7F guiding catheter without side holes is introduced to 
the coronary ostium. After the intracoronary 
administration of 100–200 µg nitroglycerin, 0.3556-mm 
(0.014-inch) pressure guide wire is advanced to the tip of 
the guiding catheter, where the pressure measured 
through the guiding catheter and the pressure measured 
with the guide wire are verified as being equal. The 
pressure wire is then advanced into the coronary artery 
across the stenosis to the most distal part of the vessel, 
while the tip of pressure guide wire is free within the 
vessel lumen and not against the vessel wall. The aortic 
pressure and distal coronary pressure are measured 
simultaneously in a maximum hyperemic state induced 
by a vasodilator agent either intracoronary (IC) bolus 
administration or continuous intravenous (IV) infusion, 
and FFR is then determined.11,12 
 
The pharmacologic vasodilator stimuli include adenosine, 
adenosine 5′-triphosphate (ATP), papaverine, nitro- 
prusside or dobutamine. Due to the rapid onset and short 
duration of action, cost effectiveness, high safety profile, 
simplicity and facility, steady state, the most widely used 
pharmacologic agent to induce coronary hyperemia for 
FFR measurement is adenosine.3,4,6 Because the distal 
coronary artery pressure is influenced by both epicardial 
stenosis and distal resistance, maximal hyperemia is a key 
determinant for FFR measurement in a fixed epicardial 
stenosis. Less than maximal vasodilation would 
overestimate the FFR, which might result in an 
underestimation of stenosis severity and lead to erroneous 
clinical decisions in patients with intermediate stenosis. 
The regularly recommended dosage for intracoronary 
adenosine bolus injection is 15–30 µg for the right 
coronary artery (RCA) and 20–40 µg for the left coronary 
artery (LCA), intravenous adenosine infusion dosage is 
140 µg·kg-1·min-1.5,7 
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APPLICATION 
 
Intermediate coronary stenosis (40%–70%) 
FFR assessment is an accurate diagnostic method for 
determining the physiological significance of an 
intermediate coronary lesion and distinguishes 
ischemia-producing lesions from those that do not. It has 
been shown that patients with an FFR of >0.75, deferral 
of percutaneous coronary intervention (PCI) or coronary 
artery bypass grafting (CABG) are safe and result in an 
excellent clinical outcome. Deferral of unnecessary 
coronary revascularization of non flow-limiting stenoses 
by pressure measurements may reduce procedural costs 
and the need for repeated revascularization. Therefore, 
only patients with an FFR of <0.75, which regards as 
indicative of a functionally important stenosis, need a PCI 
or CABG.2,3,8,13 A recent study by Verna et al14 
demonstrated that unnecessary PCI may be saved in more 
than one half of individual coronary stenoses and there 
was not a nonlinear correlation between FFR and 
quantitative coronary angiography (QCA). The risk of 
major adverse cardiac events (MACE) and target vessel 
revascularization (TVR) in patients with FFR >0.75 and 
deferral of PCI was lower than the risk associated with 
PCI. In their study on 112 patients with 175 stenoses 
including 71 multivessel coronary artery disease patients 
(MVD) (63%) and 30 patients (27%) with unstable 
symptoms, based on the results of FFR, PCI was deferred 
in 67 stenoses in 54 patients (FFR >0.75, group I). In the 
remaining 58 patients (group II) with 108 diseased 
vessels, PCI was performed in one or more functionally 
significant stenoses (FFR <0.75) and deferred in 
nonsignificant stenoses (FFR >0.75). During a median 
period of 34 months follow-up, MACE occurred in 12.9% 
of group I patients and in 24.1% of group II patients, 
TVR was required in 5% of the stenoses untreated based 
on FFR result in both groups and in 12.6% of stenoses 
that underwent PCI.  
 
Multivessel coronary artery disease (MVD) 
In patients with MVD, it is attractive to have techniques 
to determine which particular culprit lesion is 
physiologically significant and is responsible for 
reversible ischemia. Since FFR is a reliable and 
lesion-specific index of stenosis severity, it is possible to 
identify one or more culprit lesions in such patients, when 
PCI or CABG can be avoided and performed, even if 
initially planned on the basis of visual assessment by the 
angiogram.12,15 Wongpraparut et al16 analyzed 137 
patients (312 vessels) with MVD to compare FFR-guided 
PCI (PCI of stenosis with an FFR <0.75) to conventional 
PCI (PCI was performed by visual estimation of the 
stenosis). In the FFR-guided PCI group (57 patients with 
128 stenoses), PCI was performed in 48 patients (53 
stenoses). In the conventional PCI group (80 patients with 
184 stenoses), all patients underwent PCI. The average 
number of stenoses per patient that underwent PCI and 
the cost of the procedure were significantly higher in the 
conventional PCI group compared to the FFR-guided PCI 
group (2.27±0.50 vs 1.12±0.30 stenoses and 3167±1194 
dollars vs 2572± 934 dollars, respectively; P <0.001). 
During a 30-month follow-up period, FFR-guided PCI 
significantly reduced the number of TVR and MACE (5% 
vs 23% and 8% vs 27%, respectively; P <0.01), increased 
event-free survival estimate (89% vs 59%, P <0.01). 
Nevertheless, the optimal revascularization strategy (PCI 
or CABG) remains a problem for patients with MVD. 
Botman et al17 compared the long-term outcomes of 
patients with MVD undergoing selective PCI of only 
hemodynamically significant lesions (FFR <0.75) to 
patients undergoing CABG of all stenoses. One hundred 
and fifty patients with MVD (381 coronary arteries) 
referred for CABG. If the FFR was <0.75 in three vessels 
or if the FFR was <0.75 in two vessels including the 
proximal left anterior descending artery (LAD), CABG 
was performed (CABG group). If only one or two vessels 
were physiologically significant (not including the 
proximal LAD), PCI of those lesions was performed (PCI 
group). Of the 150 patients, there were 87 patients who 
fulfilled the criteria for CABG and 63 patients for PCI. At 
2-year follow-up, no differences were found in the 
number of MACE including death, acute myocardial 
infarction (AMI), repeat revascularization and anginal 
status. Recently, a large multicenter, randomized trial 
(FAME study) by Tonino et al18 demonstrated that routine 
FFR measurement of all lesions in patients with MVD 
significantly reduced MACE at 1 year when only PCI 
with drug-eluting stents was performed in lesions with 
FFR <0.80. One thousand and five patients with MVD 
were randomly assigned to undergo PCI guided by 
angiography alone or guided by FFR measurements in 
addition to coronary angiography. The number of stents 
used per patient was 2.7±1.2 and 1.9±1.3, respectively (P 
<0.001). The 1-year event rate and percentage of patients 
free from angina were 18.3% and 78%, respectively in 
the angiography group, 13.2% and 81% in the 
FFR-guided PCI group, respectively (P=0.02 and P=0.20). 
This trial confirmd that the use of FFR measurement was 
useful, safe and seemed cost-effective. 
 
Diffuse and serial diseased lesions 
Diffuse disease, multiple sequential stenoses or plaques 
are commonly present and an objective selection of the 
most appropriate stenosis to be dilated out of several in 
sequence is an important interventional decision. FFR 
measurement is extremely useful in guiding spot-stenting 
in a vessel with long and diffuse lesions by performing 
the pressure pullback maneuver. It is known that coronary 
atherosclerosis is a diffuse process and QCA does not 
always reflect this. De Bruyne et al5 obtained FFR in 37 
arteries in 10 individuals without atherosclerosis (group I) 
and in 106 nonstenotic arteries in 62 patients with 
arteriographic stenoses in another coronary artery (group 
II). In group I, the pressure gradient between aorta and 
distal coronary artery was minimal at rest ((1±1) mmHg) 
and during maximal hyperemia ((3±3) mmHg), 
corresponding values were significantly higher in group 
II ((5±4) mmHg and (10±8) mmHg, respectively; both P 
Chinese Medical Journal 2009;122(6):725-731 727
<0.001). The FFR was near unity (0.97±0.02) in group I, 
but it was significantly lower (0.89 ±0.08) in group II. In 
8% of arteries in group II, FFR was <0.75, the threshold 
for inducible ischemia. Accordingly, using pressure 
pull-back recording at maximum hyperemia can provide 
the necessary information to decide if and where stenting 
is useful. The location of a focal pressure drop 
superimposed on the diffuse disease can be identified as 
appropriate location for treatment. On the other hand, the 
decline of pressure along the vessel might be so diffuse 
that interventional treatment is not possible, 
multivessel/lesion stenting can be avoided and medical 
treatment or CABG is recommended.4 Sant'Anna et al19 
described a patient with stable angina and a severe lesion 
in LAD. The FFR was 0.37 during maximum hyperemia. 
After stent implantation, the FFR was only 0.75 despite 
the excellent angiographic result. When the pressure wire 
was slowly drawn back from the distal portion of LAD to 
its proximal portion, a continuous and gradual increase in 
intracoronary pressure was noted, but was not observed in 
the stent and the patient was asymptomatic.  
 
For patients with multiple sequential stenoses or diffuse 
coronary artery disease in the same vessel, a stepwise or 
more gradual decrease in pressure along the artery can be 
expected during maximum hyperemia. These longitudinal 
pressure changes can be measured by positioning the 
pressure wire distal in the coronary artery and pulling it 
back slowly to the ostium during sustained myocardial 
hyperemia with vasodilating stimulus persistently given 
intravenously. In this instance, the hyperemic flow and 
pressure gradient through the first one will be influenced 
by the presence of the second one and vice versa. One 
stenosis will mask the true effect of its serial counterpart 
by limiting the ability to achieve maximum hyperemia. 
The fluid dynamic interaction between two serial stenoses 
depends on the sequence, severity, and distance between 
the lesions as well as the flow rate. When the distance 
between two lesions is greater than six times the vessel 
diameter, they generally behave independently and the 
overall pressure gradient is the sum of the individual 
pressure losses at any given flow rate. The precise clinical 
assessment of each lesion by FFR separately is possible 
but remains academic as the coronary wedge pressure 
(during artery occlusion) is needed to perform these 
calculations. In clinical practice, the stenosis with the 
largest gradient can be treated first and FFR can be 
remeasured for the remaining stenosis to determine the 
need for further treatment.4,10  
 
Bifurcation lesions 
Assessment of severity of coronary stenosis and PCI in 
bifurcation lesion remains one of the most challenging 
lesion subsets in PCI. Treatment of this lesion is 
associated with low procedural success and high 
complication and restenosis rates.20 Angiographic 
assessment of the severity of bifurcation lesions is 
hampered by the inherent limitations of angiography, 
especially overlap of adjacent vessels, angulation, and 
foreshortening of the origin of the side branch. Therefore, 
it is still not clear which side branches should be treated 
after stent implantation of the main branch lesion and 
how to assess the functional significance of these lesions. 
Koo et al21 investigated 97 jailed side branch lesions 
(vessel size >2.0 mm, percent stenosis >50% by visual 
estimation) after stent implantation at main branches and 
found that mean FFR was 0.94±0.04 and 0.8±0.11 at the 
main branches and jailed side branches, respectively. 
There was a negative correlation between the percent 
stenosis and FFR (r=0.41, P <0.001). However, no lesion 
with <75% stenosis had FFR <0.75. Among 73 lesions 
with ≥75% stenosis, only 20 lesions were functionally 
significant. Thus, most of the lesions involving the jailed 
side branch might not have functional significance and do 
not require PCI. The use of FFR in the assessment of 
bifurcation lesions might prevent unnecessary 
interventions in lesions that are not functionally 
restrictive. The need for revascularization of the side 
branch in bifurcation lesions can be guided by 
hemodynamic parameters as determined by FFR. 
 
Left main coronary artery stenosis (LMCS) 
In view of the shortcoming of angiography and the 
limitation of QCA analysis, the angiographic assessment 
of LMCS may often be particularly difficult and 
unreliable and may not correlate with its functional 
significance. Furthermore, autopsy reports have shown 
many LMCS were mildly diseased, but were often 
reported as significantly stenosed by angiography.22,23  It 
has been established that withdrawal from intervention in 
patients with isolated borderline LMCS with FFR ≥0.75 
is safe and associated with favourable clinical 
outcomes.24,25 A study by Jasti et al22 demonstrated that 
when decision-making about revascularization was based 
on physiological data, a significant number of patients 
(37 patients in 55 patients) can be spared from 
unnecessary CABG or PCI, and that in patients with an 
ambiguous LMCS, a decision based on an FFR cut point 
of 0.75 to proceed with revascularization or medical 
therapy was associated with excellent 38-month survival 
and event-free survival rates. Lindstaedt et al 23 observed 
51 patients with intermediate LMCS (40%–80%). If FFR 
was <0.75 along the LM, CABG was recommended, if 
FFR was >0.80, medical treatment or PCI elsewhere in 
the coronary tree was chosen. After mean follow-up of 
(29±16) months, estimated survival and event-free 
survival were 81% and 66% respectively in the CABG 
and in the non CABG 100% and 69% respectively.  
 
Evaluating the results of implanted stents 
The restenosis rates after implanting a bare-metal stent 
(BMS) or a drug-eluting stent (DES) are 20%–40% and 
5%–10%, respectively and it is probably higher in 
complex coronary lesions. Because normal epicardial 
coronary arteries provide no resistance to blood flow, 
optimum coronary stenting should at least result in the 
disappearance of any hyperemic pressure drop within the 
treated coronary segment.6,22 FFR has been proposed for 
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the assessment of optimal stent deployment while QCA 
alone is not a precise technique to detect local areas of 
incomplete stent expansion.10 A resent study in 119 
patients performed by Klauss et al26 has shown that a 
post-interventional FFR >0.95 was a significant and 
independent predictor for developing adverse cardiac 
events (death, MI, TVR) and post-interventional FFR 
<0.95 increased the risk of adverse outcome about sixfold 
compared to FFR ≥0.95 during a follow-up of 6 months. 
In addition, Pijls et al1 demonstrated in a study with 750 
patients and apparently satisfactory stent implantation 
(residual diameter stenosis <10% by visual estimation) 
that FFR was a strong independent predictor of outcome 
at 6 months; the higher the post-stenting FFR, the lower 
the MACE. For patients with a post-stenting FFR >0.95, 
the MACE was 4.9%; for values between 0.90 and 0.95, 
it was 6.2%; for values between 0.80 and 0.90, it was 
20.3%; and for post-stenting FFR <0.80, the MACE was 
29.5% (P <0.001). 
 
In-stent restenosis (ISR) 
The main limitation of implanting stents is ISR and the 
optimal treatment strategy of ISR remains unclear. 
Although some treatments (cutting balloon angioplasty, 
vascular brachytherapy, DES) have been used, ISR is still 
not eliminated and is expensive to treat. Therefore, it is 
clinically important to identify patients with a favourable 
clinical outcome, who are not expected to obtain further 
benefit from additional interventional treatment. The best 
way is to prevent unnecessary treatment in a patient with 
a nonsignificant ISR. The use of FFR >0.75 in these 
patients with moderate or intermediate ISR can safely 
avoid new complex and expensive unnecessary TVR 
based solely on QCA and results in a better clinical 
outcome. Krüger et al27 studied 42 patients with 
intermediate ISR (40%–70%) and found that FFR 
averaged 0.77±0.15 and was <0.75 in 20 patients. In the 
22 stented patients with an FFR >0.75, no MACE 
occurred related to the stented lesion in the subsequent 6 
months. Another study by Lopez-Palop et al28 also 
demonstrated that QCA was of no value in discriminating 
functional significance of ISR <70% measured by visual 
assessment. In their study on 65 lesions in 62 patients 
with angiographically intermediate ISR (40%–70%), an 
FFR value >0.75 was obtained in 41 lesions (63%), 21 of 
them with stenosis ≥50%. The co-efficient of correlation 
between parameters of QCA and FFR value was <0.5, 
furthermore, no events related to the non-treated lesions 
were observed. 
                      
LIMITATION 
 
Dosages and approach 
Induction of maximal hyperemia is a prerequisite for a 
reliable estimation of FFR, but the optimal dosing to 
achieve maximal vasodilation is still unclear.10,29 A lot of 
studies showed that recommended standard dose of 
adenosine was usually sufficient to cause maximal 
hyperemia in both the RCA and LCA systems. However, 
for some patients especially in patients with FFR in the 
borderline range of 0.75–0.80, a higher dose of adenosine 
was needed to ensure maximal hyperemia, otherwise 
lesion severity would be underestimated and subsequent 
treatment would be inappropriate. Casella et al30 
demonstrated that high doses of IC adenosine up to 150 
µg were needed to ensure maximal hyperemia in some 
patients, and such high doses were safe and associated 
with few adverse systemic effects compared with the 
standard dose. 
 
Many data indicated that intracoronary bolus injection 
was equivalent to intravenous infusion for determination 
of FFR in a large majority of patients, however, studies 
have demonstrated that IC adenosine was sometimes 
inadequate for the induction of maximal hyperemia and a 
repeated higher IC adenosine may be helpful.31,32 
Intravenous infusion requires a large venous access, a 
large amount of adenosine and a longer procedure time. 
With IC adenosine, the duration of the hyperemic state is 
sometimes too short for a pressure pullback maneuver 
and it is not recommended in ostial stenosis.33 Koo et 
al10 demonstrated that intracoronary infusion 180–240 
µg/min of adenosine was also a safe and effective 
method of inducing maximal hyperemia for FFR 
measurement. 
 
Grey zone of the ischemic threshold (FFR value 0.75 
–0.80) 
The FFR range of 0.75 to 0.80 is commonly considered to 
be the “grey zone” in which clinical judgement must 
complement quantitative assessments in forming the final 
treatment decision. Still a small number of patients with 
an FFR between 0.75 and 0.80 have proven inducible 
ischemia.34 Hence, deferral of PCI may be unjustified for 
some patients. In fact, similar mean FFR values have 
been reported in studies that used the cut-off values of 
0.80 rather than 0.75 to defer coronary 
revascularization.23,35 Previous studies have suggested 
that deferring coronary revascularization in moderate 
coronary lesions with FFR values in the “grey zone” 
might be associated with a higher rate of cardiac events. 
Legalery et al35 reported a cardiac event rate of 21% at 
1-year follow-up in a group of 34 patients who did not 
undergo revascularization on the basis of FFR values 
between 0.75 and 0.79. Also, Chamuleau et al36 identified 
an FFR value of 0.79 as the best cut-off point to predict 
cardiac events during follow-up. Therefore, it may be of 
clinical importance in some patients, when FFR is 
0.75–0.80, and a change of 0.05 reclassifies the lesion 
from amenable for conservative therapy to a lesion which 
should be treated invasively.4,30 Rzeczuch et al37 have 
demonstrated that an increase of the intracoronary 
adenosine dose from 30 to 60 µg was well tolerated and 
caused further decrease in the FFR values in 36 patients 
with 53 moderate coronary lesions. The mean value of 
FFR30 was significantly higher than FFR60 (0.854± 0.152 
vs 0.836±0.162, P <0.001). In 29 (54.7%) evaluated 
lesions, FFR30 values were higher than FFR60; in 12 
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(22.6%) measurements the difference exceeded 0.02, and 
in 8 (15%) cases exceeded 0.05. Thus, the use of a 
standard dose of adenosine may artificially increase the 
FFR value and cause erroneous selection for conservative 
therapy. Barbato et al29 discovered that if FFR was 
between 0.75 and 0.80, administration of adrenergic 
blockade (phentolamine and urapidil, especially latter) 
dropped the value of FFR from above 0.75 to below this 
threshold value in some patients. Another study by 
Aarnoudse et al38 showed that in 15 patients who did not 
have microvascular disease, no differences in hyperemic 
response to adenosine were noted, whether or not 
α-blockade (3 mg of intracoronary infusion phentolamine) 
was given before adenosine administration. In another 15 
patients who had microvascular disease, some increases 
in hyperemic response were observed after administration 
of phentolamine and FFR levels decreased from 0.74 to 
0.70 using intracoronary adenosine (P=0.003) and from 
0.75 to 0.72 using intravenous adenosine (P=0.04). 
Therefore, in selected patients who have clear 
microvascular dysfunction and in which FFR is in the 
grey zone (0.75 to 0.80), additional intracoronary 
administration of phentolamine can be used to ensure the 
presence of truly maximum hyperemia. 
 
Myocardial infarction (MI) and microvascular disease 
In the absence of a stenosis and collaterals, the 
myocardial flow is equal to coronary flow. In the case of 
a stenosis with collaterals, however, myocardial flow is 
not equal to coronary flow but increasingly exceeds 
coronary flow due to the collateral flow.39 More recent 
studies have suggested that microvascular resistance 
paradoxically increases with increasing stenosis 
severity.2,40-42 The presence of previous MI may blunt the 
maximal hyperemic response, which has been attributed 
to infarct-related microvascular dysfunction. As the 
coronary blood flow in AMI patients with microvascular 
damage is restricted, the pressure drop across the stenosis 
during hyperemia may be smaller than expected. 
However, although the effects of microvascular 
dysfunction on FFR in MI patients remain undetermined, 
microvascular dysfunction is likely to restrict coronary 
flow dynamics.39,43 In such cases, the FFR may not 
accurately reflect the degree of coronary lesion severity 
and underestimate it. FFR can be influenced by several 
factors including time after the onset of MI, myocardial 
stunning or hibernation, severity of the stenosis, infarct 
size and the presence of collateral blood flow. Tamita et 
al43 compared 33 AMI patients within 12 hours to 15 
patients with stable angina pectoris. Assessment of the 48 
lesions by means of intravascular ultrasound (IVUS) and 
FFR measurements after successfully stenting showed 
that post-interventional FFR was higher in AMI 
compared with angina pectoris patients (0.95±0.04 vs 
0.90±0.04; P=0.002), although there were no significant 
differences in IVUS. AMI patients were assigned to two 
subgroups based on their post-procedural Thrombolysis 
on Myocardial Infarction (TIMI) flow grade (23 patients 
with TIMI 3 and 10 with TIMI 2). There were no 
differences in IVUS between the AMI subgroups, while 
FFR was higher in the patients with TIMI 2 compared to 
those with TIMI 3 (0.98±0.02 vs 0.93±0.05; P=0.017). 
Tani et al39 also discovered two patients after AMI with 
related wall ischemia by single-photon emission 
computed tomography (SPECT), one with a 73% 
coronary stenosis in RCA and one with 68% coronary 
stenosis in LAD. The FFR was 0.89 and 0.87, 
respectively. Therefore, FFR measurements in the 
residual stenosis of the culprit lesion after MI must be 
interpreted with caution. However, Samady et al44 studied 
48 patients after MI (3.7±1.3) days and compared the 
relationship of FFR with myocardial contrast 
echocardiography (MCE) and SPECT. The optimal FFR 
value for discriminating inducible ischemia on 
noninvasive imaging was 0.78. This finding demonstrated 
that FFR of the infarct-related artery accurately identified 
reversibility on noninvasive imaging early after MI and 
supported the utility of FFR early after MI. Another 
recent study by Fischer et al 45 showed that deferral of 
revascularization based on FFR ≥0.75 in patients with 
acute coronary syndromes (ACS) and moderate coronary 
stenoses was associated with acceptable and low event 
rates at 1 year. In their study, revascularization was 
deferred in 120 lesions (111 patients) with FFR ≥0.75. 
ACS was present in 35 patients (40 lesions). The 35 
patients with ACS consisted of three patients (four lesions) 
with unstable angina, 11 patients (13 lesions) with recent 
(within 7 days) ST segment elevation MI and 21 patients 
(23 lesions) with non-ST segment elevation MI. Among 
the 35 patients with ACS, there were 3 deaths, 1 MI, and 
6 TVR, among the 76 patients without ACS, there were 5 
deaths, 1 MI, and 7 TVR (P <0.05, respectively).  
                      
CONCLUSIONS 
 
FFR has offered a new and convenient method for 
choosing PCI or CABG versus conservative treatment. 
Furthermore, it can be used to evaluate and predict the 
result of PCI in single vessel disease, MVD and LMCS. 
The value of FFR has been demonstrated by many 
experimental and clinical studies, but still requires further 
investigation to determine its overall significance, 
particularly in diffuse and complex lesions and after MI. 
However, most of the former studies with FFR were 
performed in patients with bare metal stents, and it needs 
further investigation to demonstrate if these results of the 
application and value of FFR can be extrapolated to 
patients with drug-eluting stents. 
                                          
REFERENCES 
 
1. Pijls NH, Klauss V, Siebert U, Powers E, Takazawa K, Fearon 
WF, et al. Coronary pressure measurement after stenting 
predicts adverse events at follow-up: a multicenter registry. 
Circulation 2002; 105: 2950-2954. 
2. Yanagisawa H, Chikamori T, Tanaka N, Usui Y, Takazawa K, 
Yamashina A. Application of pressure-derived myocardial 
fractional flow reserve in assessing the functional severity of 
Chin Med J 2009;122(6):725-731 730 
coronary artery stenosis in patients with diabetes mellitus. 
Circ J 2004; 68: 993-998. 
3. Aude YW, Garza L. How to prevent unnecessary coronary 
interventions: identifying lesions responsible for ischemia in 
the cath lab. Curr Opin Cardiol 2003; 18: 394-399. 
4. Kern MJ, Lerman A, Bech JW, De Bruyne B, Eeckhout E, 
Fearon WF, et al. Physiological assessment of coronary artery 
disease in the cardiac catheterization laboratory: a scientific 
statement from the American Heart Association Committee on 
Diagnostic and Interventional Cardiac Catheterization, 
Council on Clinical Cardiology. Circulation 2006; 114: 
1321-1341. 
5. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, 
Heyndrickx GR, et al. Abnormal epicardial coronary 
resistance in patients with diffuse atherosclerosis but 
“Normal” coronary angiography. Circulation 2001; 104: 
2401-2406. 
6. Hau WK. Fractional flow reserve and complex coronary 
pathologic conditions. Eur Heart J 2004; 25: 723-727. 
7. Fearon WF, Luna J, Samady H, Powers ER, Feldman T, Dib N, 
et al. Fractional flow reserve compared with intravascular 
ultrasound guidance for optimizing stent deployment. 
Circulation 2001; 104: 1917-1922. 
8. Wijpkema JS, Vander Vleuten PA, Jessurun GA, Tio RA. 
Long-term safety of intracoronary haemodynamic assessment 
for deferral of angioplasty in intermediate coronary stenoses: a 
5-year follow-up. Acta Cardiol 2005; 60: 207-211. 
9. Yanagisawa H, Chikamori T, Tanaka N, Hatano T, Morishima 
T, Hida S, et al. Correlation between thallium-201 myocardial 
perfusion defects and the functional severity of coronary 
artery stenosis as assessed by pressure-derived myocardial 
fractional flow reserve. Circ J 2002; 66: 1105-1109. 
10. Koo BK, Kim CH, Na SH, Youn TJ, Chae IH, Choi DJ, et al. 
Intracoronary continuous adenosine infusion. Circ J 2005; 69: 
908-912. 
11. Pijis NH, De Bruyne B, Bech GJ, Liistro F, Heyndrickx GR, 
Bonnier HJ, et al. Coronary pressure measurement to assess 
the hemodynamic significance of serial stenoses within one 
coronary artery: validation in humans. Circuiation 2000; 102: 
2371-2377. 
12. Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J, 
Heyndrickx GR, et al. Long-term clinical outcome after 
fractional flow reserve-guided percutaneous coronary 
intervention in patients with multivessel disease. J Am Coll 
Cardiol 2005; 46: 438-442. 
13. Dias CC, Mateus P, Bettencourt N, Rodriques A, Goncalves M, 
Braqa JP, et al. Value of fractional flow reserve in the 
management of patients with moderate coronary stenosis. Rev 
Port Cardil 2004; 23: 1409-1416. 
14. Verna E, Lattanzio M, Ghiringhelli S, Provasoli S, Caico SI. 
Performing versus deferring coronary angioplasty based on 
functional evaluation of vessel stenosis by pressure 
measurements: a clinical outcome study. J Cardiovasc Med 
2006; 7: 169-175. 
15. Jimenez-Navarro MF, Alonso-Briales J, Hernandez-Garcia JM, 
Curiel E, Kuhlmorqen B, Gomez-Doblas JJ, et al. Usefulness 
of fractional flow reserve in multivessel coronary artery 
disease with intermediate lesions. J Interv Cardiol 2006; 19: 
148-152. 
16. Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, 
Chandra M, Masden R, et al. Thirty-month outcome after 
fractional flow reserve-guided versus conventional multivessel 
percutaneous coronary intervention. Am J Cardiol 2005; 96: 
877-884. 
17. Botman KJ, Pijls NH, Bech JW, Aarnoudse W, Peels K, Van 
Straten B, et al. Percutaneous coronary intervention or bypass 
surgery in multivessel disease? A tailored approach based on 
coronary pressure measurement. Catheter Cardiovasc Interv 
2004; 63: 184-191. 
18. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t 
Veer M, et al. Fractional flow reserve versus angiography for 
guiding percutaneous coronary intervention. N Engl J Med 
2009; 360: 213-224.  
19. Sant'Anna FM, Silva EE, Batista LA, Ventura FM, Barrozo 
CA, Pijls NH. Diffuse atherosclerotic disease unmasked by 
invasive physiologic assessment of coronary flow. Arq Bras 
Cardiol 2005; 85: 135-137. 
20. Al Suwaidi J, Yeh W, Cohen HA, Detre KM, Williams DO, 
Holmes DR Jr. Immediate and one-year outcome in patients 
with coronary bifurcation lesions in the modern era (NHLBI 
dynamic registry). Am J Cardiol 2001; 87: 1139-1144.  
21. Koo BK, Kang HJ, Youn TJ, Chae IH, Choi DJ, Kim HS, et al. 
Physiologic assessment of jailed side branch lesions using 
fractional flow reserve. J Am Coll Cardiol 2005; 46: 633-637. 
22. Jasti V, Ivan E, Yalamanchili V, Wongpraparut N, Leesar MA. 
Correlations between fractional flow reserve and intravascular 
ultrasound in patients with an ambiguous left main coronary 
artery stenosis. Circulation 2004; 110: 2831-2836. 
23. Lindstaedt M, Yazar A, Germing A, Fritz MK, Holland-Letz T, 
Mügge A, et al. Clinical outcome in patients with intermediate 
or equivocal left main coronary artery disease after deferral of 
surgical revascularization on the basis of fractional flow 
reserve measurements. Am Heart J 2006; 152:156.e1-e9. 
24. Legutko J, Dudek D, Rzeszutko L, Wizimirski M, Dubiel JS. 
Fractional flow reserve assessment to determine the 
indications for myocardial revascularisation in patients with 
borderline stenosis of the left main coronary artery. Kardiol 
Pol 2005; 63: 499-506. 
25. Jiménez-Navarro M, Hernández-García JM, Alonso-Briales 
JH, Kühlmorgen B, Gómez-Doblas JJ, García-Pinilla JM, et al. 
Should we treat patients with moderately severe stenosis of 
the left main coronary artery and negative FFR results? J 
Invasive Cardiol 2004; 16: 398-400. 
26. Klauss V, Erdin P, Rieber J, Leibig M, Stempfle HU, König A, 
et al. Fractional flow reserve for the prediction of cardiac 
events after coronary stent implantation: results of a 
multivariate analysis. Heart 2005; 91: 203-206.  
27. Krüger S, Koch KC, Kaumanns I, Merx MW, Hanrath P, 
Hoffmann R. Clinical significance of fractional flow reserve 
for evaluation of functional lesion severity in stent restenosis 
and native coronary arteries. Chest 2005; 128: 1645-1649. 
28. Lopez-Palop R, Pinar E, Lozano I, Saura D, Picó F, Valdés M. 
Utility of the fractional flow reserve in the evaluation of 
angiographically moderate in-stent restenosis. Eur Heart J 
2004; 25: 2040-2047. 
29. Barbato E, Bartunek J, Aarnoudse W, Vanderheyden M, 
Staelens F, Wijns W, et al. Alpha-adrenergic receptor blockade 
and hyperaemic response in patients with intermediate 
Chinese Medical Journal 2009;122(6):725-731 731
coronary stenoses. Eur Heart J 2004; 25: 2034-2039.  
30. Casella G, Leibig M, Schiele TM, Schrepf R, Seelig V, 
Stempfle HU, et al. Are high doses of intracoronary adenosine 
an alternative to standard intravenous adenosine for the 
assessment of fractional flow reserve? Am Heart J 2004; 148: 
590-595. 
31. Di Segni E, Higano ST, Rihal CS, Holmes DR Jr, Lennon R, 
Lerman A. Incremental doses of intracoronary adenosine for 
the assessment of coronary velocity reserve for clinical 
decision making. Cathet Cardiovasc Interv 2001; 54: 34-40. 
32. Lopez-Palop R, Saura D, Pinar E, Lozano I, Pérez-Lorente F, 
Picó F, et al. Adequate intracoronary adenosine doses to 
achieve maximum hyperaemia in coronary functional studies 
by pressure derived fractional flow reserve: a dose response 
study. Heart 2004; 90: 95-96. 
33. De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, 
Wijns W, et al. Intracoronary and intravenous adenosine 
5'-triphosphaste, adenosine, papaverine, and contrast medium 
to assess fractional flow reserve in humans. Circulation 2003; 
107: 1877-1883. 
34. Chamuleau SA, Meuwissen M, van Eck-Smit BL, Koch KT, 
de Jong A, de Winter RJ, et al. Fractional flow reserve, 
absolute and relative coronary blood flow velocity reserve in 
relation to the results of technetium-99m sestamibi 
single-photon emission computed tomography in patients with 
two-vessel coronary artery disease. J Am Coll Cardiol 2001; 
37: 1316-1322. 
35. Legalery P, Schiele F, Seronde MF, Meneveau N, Wei H, 
Didier K, et al. One-year outcome of patients submitted to 
routine fractional flow reserve assessment to determine the 
need for angioplasty. Eur Heart J 2005; 26: 2623-2629. 
36. Chamuleau SA, Meuwissen M, Koch KT, van Eck-Smit BL, 
Tio RA, Tijssen JG, et al. Usefulness of fractional flow reserve 
for risk stratification of patients with multivessel coronary 
artery disease and an intermediate stenosis. Am J Cardiol 2002; 
89: 377-380. 
37. Rzeczuch K, Jankowska E, Kaczmarek A, Telichowski A, 
Porada A, Banasiak W, et al. Measurement of coronary 
fractional flow reserve. Standard doses of intracoronary 
adenosine are insufficient to induce maximal hyperaemia. 
Kardio Pol 2003; 58: 269-274. 
38. Aarnoudse W, Geven M, Barbato E, Botman KJ, De Bruyne B, 
Pijls NH. Effect of phentolamine on the hyperemic response to 
adenosine in patients with microvascular disease. Am J 
Cardiol 2005; 96: 1627-1630. 
39. Tani S, Watanabe I, Kobari C, Matsumoto M, Miyazawa T, 
Iwamoto Y, et al. Mismatch between results of myocardial 
fractional flow reserve (FFR) measurements and myocardial 
perfusion SPECT for identification of the severity of ischemia: 
pitfall of FFR in patients with prior myocardial infarction. Jpn 
Heart J 2004; 45: 867-872.  
40. Sambuceti G, Marzilli M, Fedele S, Marini C, L'Abbate A. 
Paradoxical increase in microvascular resistance during 
tachycardia downstream from a severe stenosis in patients 
with coronary artery disease: reversal by angioplasty. 
Circulation 2001; 103: 2352-2360. 
41. Chamuleau SA, Siebes M, Meuwissen M, Koch KT, Spaan JA, 
Piek JJ. Association between coronary lesion severity and 
distal microvascular resistance in patients with coronary artery 
disease. Am J Physiol Heart Circ Physiol 2003; 285: 
H2194-H2200 
42. Marzilli M, Sambuceti G, Fedele S, L'Abbate A. Coronary 
microcirculatory vasoconstriction during ischemia in patients 
with unstable angina. J Am Coll Cardiol 2000; 35: 327-334. 
43. Tamita K, Akasaka T, Takagi T, Yamamuro A, Yamabe K, 
Katayama M, et al. Effects of microvascular dysfunction on 
myocardial fractional flow reserve after percutaneous 
coronary intervention in patients with acute myocardial 
infarction. Catheter Cardiovasc Inter 2002; 57: 452-459. 
44. Samady H, Lepper W, Powers ER, Wei K, Ragosta M, Bishop 
GG, et al. Fractional flow reserve of infarct-related arteries 
identifies reversible defects on noninvasive myocardial 
perfusion imaging early after myocardial infarction. J Am Coll 
Cardiol 2006; 47: 2187-2193. 
45. Fischer JJ, Wang XQ, Samady H, Sarembock IJ, Powers ER, 
Gimple LW, et al. Outcome of patients with acute coronary 
syndromes and moderate coronary lesions undergoing deferral 
of revascularization based on fractional flow reserve 
assessment. Catheter Cardiovasc Interv 2006; 68: 544-548. 
 
(Received February 2, 2009) 
      Edited by WANG Mou-yue
  
 
